Pelthos Therapeutics Inc.
PTHS NYSE Biological Products, (No Diagnostic Substances) Financials FY2022โFY2025
Last close ยท Oct 23, 2026
$17.00
13.2%
Revenue
Total sales reported in the income statement.
$16.8M
vs prior year
Operating margin
Operating income as a share of revenue.
โ193.1%
Net income
Profit after all expenses, interest and tax.
โ$43.3M
Free cash flow
Cash from operations minus capital spending.
โ$22.7M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
$60.2M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
On โ$28.73 EPS (TTM)
What Pelthos Therapeutics Inc. does
No business description yet.
- Legal name
- Pelthos Therapeutics Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Mar 19, 2026
- Accession ยท CIK
- 0001919246-26-000013
0001919246
Revenue and margins
Pelthos Therapeutics Inc. had $16.8M of revenue in fiscal 2025.
FY22
Revenue โ
FY23
Revenue โ
FY24
Revenue $0.0M
FY25
Revenue $16.8M
Q3 '23
Revenue โ
Q4 '23
Revenue โ
Q1 '24
Revenue โ
Q2 '24
Revenue โ
Q3 '24
Revenue โ
Q4 '24
Revenue โ
Q1 '25
Revenue $0.0M
Q2 '25
Revenue $0.0M
Q3 '25
Revenue $7.4M
Q4 '25
Revenue $9.4M
Q1 '26
Revenue $10.9M
Q2 '26
Revenue $15.6M
FY22
Gross โ
Operating โ
Net โ
FCF โ
FY23
Gross โ
Operating โ
Net โ
FCF โ
FY24
Gross โ
Operating โ
Net โ
FCF โ
FY25
Gross 76.3%
Operating โ193.1%
Net โ257.9%
FCF โ135.1%
Gross
Operating
Net
FCF
Q3 '23
Gross โ
Operating โ
Net โ
FCF โ
Q4 '23
Gross โ
Operating โ
Net โ
FCF โ
Q1 '24
Gross โ
Operating โ
Net โ
FCF โ
Q2 '24
Gross โ
Operating โ
Net โ
FCF โ
Q3 '24
Gross โ
Operating โ
Net โ
FCF โ
Q4 '24
Gross โ
Operating โ
Net โ
FCF โ
Q1 '25
Gross โ
Operating โ
Net โ
FCF โ
Q2 '25
Gross โ
Operating โ
Net โ
FCF โ
Q3 '25
Gross 68.7%
Operating โ207.4%
Net โ219.3%
FCF โ
Q4 '25
Gross 82.2%
Operating โ127.8%
Net โ230.7%
FCF โ
Q1 '26
Gross 84.7%
Operating โ120.0%
Net โ229.9%
FCF โ122.1%
Q2 '26
Gross 76.9%
Operating โ111.0%
Net โ150.1%
FCF โ49.1%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY22
Net income โ$2.5M
FY23
Net income โ$7.4M
FY24
Net income โ$8.0M
FY25
Net income โ$43.3M
Q3 '23
Net income โ$1.4M
Q4 '23
Net income โ$4.0M
Q1 '24
Net income โ$2.6M
Q2 '24
Net income โ$1.8M
Q3 '24
Net income โ$1.7M
Q4 '24
Net income โ$1.9M
Q1 '25
Net income โ$2.0M
Q2 '25
Net income โ$3.4M
Q3 '25
Net income โ$16.2M
Q4 '25
Net income โ$21.7M
Q1 '26
Net income โ$25.1M
Q2 '26
Net income โ$23.4M
FY22
Diluted EPS โ
FY23
Diluted EPS โ$5.78
FY24
Diluted EPS โ$14.27
FY25
Diluted EPS โ$23.04
Q3 '23
Diluted EPS โ
Q4 '23
Diluted EPS โ
Q1 '24
Diluted EPS โ$0.55
Q2 '24
Diluted EPS โ$3.07
Q3 '24
Diluted EPS โ$2.93
Q4 '24
Diluted EPS โ$7.72
Q1 '25
Diluted EPS โ$3.21
Q2 '25
Diluted EPS โ$5.29
Q3 '25
Diluted EPS โ$5.30
Q4 '25
Diluted EPS โ$9.24
Q1 '26
Diluted EPS โ$7.57
Q2 '26
Diluted EPS โ$6.62
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY22
Return on capital โ
Return on equity โ
Return on assets โ4,462.1%
FY23
Return on capital โ
Return on equity โ
Return on assets โ9,743.6%
FY24
Return on capital โ
Return on equity โ
Return on assets โ1,085.7%
FY25
Return on capital โ
Return on equity โ239.5%
Return on assets โ65.8%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ$22.7M in fiscal 2025, โ135.1% of revenue. Cash from operations minus capital spending.
FY22
Free cash flow โ
FY23
Free cash flow โ
FY24
Free cash flow โ$5.8M
FY25
Free cash flow โ$22.7M
Q3 '23
Free cash flow โ
Q4 '23
Free cash flow โ
Q1 '24
Free cash flow โ
Q2 '24
Free cash flow โ
Q3 '24
Free cash flow โ
Q4 '24
Free cash flow โ
Q1 '25
Free cash flow โ$0.6M
Q2 '25
Free cash flow โ$0.4M
Q3 '25
Free cash flow โ
Q4 '25
Free cash flow โ
Q1 '26
Free cash flow โ$13.3M
Q2 '26
Free cash flow โ$7.7M
FY22
Cash from operations โ$1.6M
Capital spending โ
FY23
Cash from operations โ$1.0M
Capital spending โ
FY24
Cash from operations โ$5.8M
Capital spending $0.0M
FY25
Cash from operations โ$22.6M
Capital spending $0.1M
Cash from operations
Capital spending
Q3 '23
Cash from operations โ$0.3M
Capital spending โ
Q4 '23
Cash from operations โ$0.4M
Capital spending โ
Q1 '24
Cash from operations โ$2.0M
Capital spending โ
Q2 '24
Cash from operations โ$3.0M
Capital spending โ
Q3 '24
Cash from operations โ$0.2M
Capital spending โ
Q4 '24
Cash from operations โ$0.7M
Capital spending โ
Q1 '25
Cash from operations โ$0.6M
Capital spending $0.0M
Q2 '25
Cash from operations โ$0.4M
Capital spending $0.0M
Q3 '25
Cash from operations โ$15.3M
Capital spending โ
Q4 '25
Cash from operations โ$6.3M
Capital spending โ
Q1 '26
Cash from operations โ$13.1M
Capital spending $0.2M
Q2 '26
Cash from operations โ$7.7M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
Pelthos Therapeutics Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 237.4%.
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks $0.1M
FY25
Dividends โ
Buybacks $0.0M
Dividends
Buybacks
FY22
Diluted shares โ
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.00B
FY25
Diluted shares 0.00B
Balance sheet
Cash, debt and the ratios that show how comfortably Pelthos Therapeutics Inc. can carry it.
FY22
Cash $0.1M
Debt โ
FY23
Cash $0.1M
Debt โ
FY24
Cash $0.5M
Debt โ
FY25
Cash $18.0M
Debt โ
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $0.1M | $0.1M | $0.5M | $18.0M |
| Interest coverage | โ17.1x | โ22.2x | โ9.6x | โ10.8x |
| Current ratio | 0.0x | 0.0x | 0.3x | 2.1x |
| Quick ratio | 0.0x | 0.0x | 0.3x | 1.1x |
| Total assets | $0.1M | $0.1M | $1.4M | $130M |
| Total liabilities | $3.8M | $6.5M | $4.1M | $91.5M |
| Shareholders' equity | โ$3.7M | โ$6.4M | โ$2.7M | $38.9M |
| Net debt (โ = net cash) | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 5 | โ / 6 | 4 / 7 |
| Accruals ratio | โ1,618.0% | โ8,448.6% | โ295.2% | โ31.5% |
| Altman Z'' | โ1,088.25 | โ1,375.15 | โ102.01 | โ1.47 |
4 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | โ | โ | $0.0M | $16.8M |
| Gross profit | โ | โ | $0.0M | $12.8M |
| Research and development | $0.4M | $2.6M | $1.2M | $1.2M |
| Operating income | โ$2.3M | โ$6.9M | โ$7.6M | โ$32.4M |
| Interest expense | $0.1M | $0.3M | $0.8M | $3.0M |
| Pretax income | โ$2.5M | โ$7.4M | โ$8.0M | โ$50.7M |
| Income tax | โ | โ | $0.0M | โ$7.4M |
| Net income | โ$2.5M | โ$7.4M | โ$8.0M | โ$43.3M |
| Diluted EPS | โ | โ$5.78 | โ$14.27 | โ$23.04 |
| Diluted shares | โ | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||
| Cash from operations | โ$1.6M | โ$1.0M | โ$5.8M | โ$22.6M |
| Capital expenditure | โ | โ | $0.0M | $0.1M |
| Free cash flow | โ | โ | โ$5.8M | โ$22.7M |
| Depreciation and amortization | โ | โ | $0.0M | $0.7M |
| Stock-based compensation | $0.1M | $1.7M | $1.8M | $5.5M |
| Share buybacks | โ | โ | $0.1M | $0.0M |
| Dividends and buybacks | โ | โ | $0.1M | $0.0M |
| Balance sheet | ||||
| Cash and short-term investments | $0.1M | $0.1M | $0.5M | $18.0M |
| Current assets | $0.1M | $0.1M | $1.4M | $53.4M |
| Current liabilities | $3.8M | $6.5M | $4.1M | $26.0M |
| Inventory | โ | โ | $0.0M | $23.6M |
| Property and equipment, net | โ | โ | $0.0M | $9.6M |
| Goodwill | โ | โ | $0.0M | $24.7M |
| Intangible assets | โ | โ | $0.0M | $39.5M |
| Total assets | $0.1M | $0.1M | $1.4M | $130M |
| Total liabilities | $3.8M | $6.5M | $4.1M | $91.5M |
| Shareholders' equity | โ$3.7M | โ$6.4M | โ$2.7M | $38.9M |
| Margins | ||||
| Gross margin | โ | โ | โ | 76.3% |
| Operating margin | โ | โ | โ | โ193.1% |
| EBITDA margin | โ | โ | โ | โ188.8% |
| Net margin | โ | โ | โ | โ257.9% |
| FCF margin | โ | โ | โ | โ135.1% |
| Returns | ||||
| Return on capital employed | 62.5% | 106.5% | 279.0% | โ31.1% |
| Return on equity | โ | โ | โ | โ239.5% |
| Return on assets | โ4,462.1% | โ9,743.6% | โ1,085.7% | โ65.8% |
| Growth | ||||
| Share count change | โ | โ | โ56.3% | 237.4% |
| Financial health | ||||
| Interest coverage | โ17.1x | โ22.2x | โ9.6x | โ10.8x |
| Current ratio | 0.0x | 0.0x | 0.3x | 2.1x |
| Quick ratio | 0.0x | 0.0x | 0.3x | 1.1x |
| Capital allocation | ||||
| Capex / revenue | โ | โ | โ | 0.6% |
| Stock comp / revenue | โ | โ | โ | 32.5% |
| Quality scores | ||||
| Piotroski F-score | โ | โ | โ | 4.0 |
| Altman Z'' | โ1,088.3 | โ1,375.1 | โ102.0 | โ1.5 |
| Accruals ratio | โ1,618.0% | โ8,448.6% | โ295.2% | โ31.5% |
Source: SEC EDGAR XBRL filings (CIK 0001919246). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.